Potent and broadly neutralizing antibodies against sarbecoviruses induced by sequential COVID-19 vaccination
Abstract The current SARS-CoV-2 variants strikingly evade all authorized monoclonal antibodies and threaten the efficacy of serum-neutralizing activity elicited by vaccination or prior infection, urging the need to develop antivirals against SARS-CoV-2 and related sarbecoviruses. Here, we identified...
Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2024-02-01
|
Series: | Cell Discovery |
Online Access: | https://doi.org/10.1038/s41421-024-00648-1 |